MicroRNA Microarrays

A special issue of BioTech (ISSN 2673-6284).

Deadline for manuscript submissions: closed (31 January 2013) | Viewed by 211

Special Issue Information

Dear Colleagues,

After the first microRNA was discovered in 1993, those 20-22nt size non-coding antisense inhibitory RNAs very quickly moved into spotlight as a new class of genes that is playing critical role in regulation of gene expression during development and normal functioning of cells and tissues in plants or animals. During last several years thousands of new micro-RNA molecules were discovered or predicted to be an essential regulatory genes in both normal and diseases states. Profiling for miRNAs expression and search for their mRNA targets are still very challenging tasks.

Microarray technology on other hand became a standard approach when there is a need for reliable screening technique applicable for multiple biological samples and particular for genomic materials. Thus the application of microarrays for microRNA studies became a useful tool in basic research and drug discovery.

In this issue we are inviting material about new developments and applications of microarray based technologies in field of microRNA expression profiling, in screening for targeted mRNAs, in discovery of new regulatory functions of those small noncoding genes. Information about new developments associated with annotations of miRNAs in databases and data analysis for miRNA microarrays is also critical in area of microarray technologies.

Dr. Veronica Soloveva
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. BioTech is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • miRNA microarrays, microchips
  • miRNA expression
  • profiling
  • targets of miRNA
  • repression and induction by miRNA
  • viral miRNA
  • miRNA database

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to TopTop